Compare NTLA & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | DHC |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | 585 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2016 | N/A |
| Metric | NTLA | DHC |
|---|---|---|
| Price | $13.63 | $8.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 3 |
| Target Price | ★ $20.02 | $8.00 |
| AVG Volume (30 Days) | ★ 5.6M | 1.5M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.53% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | $3.13 |
| Revenue Next Year | $62.75 | $7.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $3.18 |
| 52 Week High | $28.24 | $9.14 |
| Indicator | NTLA | DHC |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 48.05 |
| Support Level | $11.55 | $8.13 |
| Resistance Level | $14.02 | $9.14 |
| Average True Range (ATR) | 0.94 | 0.31 |
| MACD | 0.11 | -0.09 |
| Stochastic Oscillator | 50.27 | 10.25 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.